Showing 4991-5000 of 5771 results for "".
- Novartis Receives FDA Approval for Beovu for Wet AMDhttps://modernod.com/news/novartis-receives-fda-approval-for-beovu-for-wet-amd/2476953/Novartis announced that the FDA approved Beovu (brolucizumab-dbll) injection, also known as RTH258, for the treatment of wet age-related macular degeneration (AMD). Beovu is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain elig
- CorneaGen Raises $37 Million to Advance Development of Cornea Cell Therapyhttps://modernod.com/news/corneagen-raises-37-million-to-advance-development-of-cornea-cell-therapy/2476950/CorneaGen announced the closing of a $37 million Series B financing. The round was led by Flying L Partners in collaboration with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology. Petrichor Healthcare Capital Management also participated in the equity round and provi
- CorneaGen Raises $37 Million to Advance Development of Cornea Cell Therapyhttps://modernod.com/news/corneagen-raises-37-million-to-advance-development-of-cornea-cell-therapy/2476948/CorneaGen announced the closing of a $37 million Series B financing. The round was led by Flying L Partners in collaboration with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology. Petrichor Healthcare Capital Management also participated significantly in the equity r
- FDA Approval Granted for Eyeris Novel Contact Lenshttps://modernod.com/news/fda-approval-granted-for-eyeris-novel-contact-lens/2476946/Eyeris, a Nashville, Tennessee start-up, announced that it has closed its second round of funding and secured FDA approval for their daily disposable contact lens, which will become available in
- Allergan Expands Refresh Portfolio With New Refresh Relieva Lubricant Eye Drop Product Linehttps://modernod.com/news/allergan-expands-refresh-portfolio-with-new-refresh-relieva-lubricant-eye-drop-product-line/2476943/Allergan announced the launch of three new over-the-counter Refresh Relieva products: Refresh Relieva, Refresh Relieva PF (preservative-free) multidose, and Refresh Relieva for Contacts. This new line of artificial tear formulations available in preserved, preservative-free multidose, and a form
- Optovue to Introduce NetVue Cloud Image Management Solutions at AAOhttps://modernod.com/news/optovue-introduces-netvue-cloud-image-management-solutions-at-aao/2476940/Optovue announced it will introduce NetVue Cloud image management software at the annual AAO meeting in San Francisco. The NetVue software provides quick access to patients’ images and data on a single screen, eliminating the need to open device-specific app
- Topline Results From Phase 2 Trial Show Nicox’s Glaucoma Drug Candidate NCX 470 Meets Primary Endpointhttps://modernod.com/news/topline-results-from-phase-2-trial-show-nicoxs-glaucoma-drug-candidate-ncx-470-meets-primary-endpoint/2476931/Nicox SA announced positive topline results from its US multicenter, Dolomites dose-response phase 2 clinical trial evaluating investigational NCX 470, a novel second-generation nitric oxide (NO)-donating bimatoprost analog, compared to latanoprost ophthalmic solution 0.005% in 433 patients with
- Product Specific J-Code for Omeros’ Omidria is Now in Effecthttps://modernod.com/news/product-specific-j-code-for-omeros-omidria-is-now-in-effect/2476927/Omeros announced that the product specific J-code for Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% is now effective. Omidria is Omeros’ commercial drug marketed for use during cataract surgery to prevent miosis and reduce postoperative pain. The new permanent J-code f
- Bausch + Lomb Enters Licensing Agreement With Intraocular Lens Design Group Tatvum Researchhttps://modernod.com/news/bausch-lomb-enters-licensing-agreement-with-intraocular-lens-design-group-tatvum-research/2476928/Bausch + Lomb announced that it has entered into a licensing agreement with Tatvum Research, a company focused on IOL development and design. Financial terms of the deal were not disclosed. The agreement provides Bausch + Lomb with worldwide commercial rights to new IOL designs for
- DORC Obtains 510k Clearance for Launch of EVA Upgrade Enhancementshttps://modernod.com/news/dorc-obtains-510k-clearance-for-launch-of-eva-upgrade-enhancements/2476922/DORC has announced 510(k) clearance for a range of enhancements to the EVA surgical system. The enhancements has been developed in close collaboration with surgeons and deliver both OR efficiency and surgical performa